e-learning
resources
Amsterdam 2011
Wednesday, 28.09.2011
Novel mechanisms in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum amyloid A augments mucosal immunity by opposing resolving lipoxinA4 signaling in chronic lung disease
S. Bozinovski, M. Uddin, R. Vlahos, M. Thompson, A. S. Merritt, P. Wark, A. Hutchinson, L. Irving, B. Levy, G. Anderson (Parkville, Newcastle, Australia; Boston, United States Of America)
Source:
Annual Congress 2011 - Novel mechanisms in COPD
Session:
Novel mechanisms in COPD
Session type:
Oral Presentation
Number:
4907
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Bozinovski, M. Uddin, R. Vlahos, M. Thompson, A. S. Merritt, P. Wark, A. Hutchinson, L. Irving, B. Levy, G. Anderson (Parkville, Newcastle, Australia; Boston, United States Of America). Serum amyloid A augments mucosal immunity by opposing resolving lipoxinA4 signaling in chronic lung disease. Eur Respir J 2011; 38: Suppl. 55, 4907
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Gut microbial modulation attenuates emphysema development by suppressing inflammation and apoptosis
Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD
Year: 2020
Airway epithelial cell P2Y6R-Expression is up-regulated during acute and chronic allergic inflammation and contributes via modulating of CXC8 and IL-6 secretion to development of airway remodelling
Source: Annual Congress 2010 - Pre-clinical models of airways disease
Year: 2010
Interferon-gamma (IFN-γ) alters the expression of IP-10 and IL-18 in human aveolar epithelial cells type II. Possible role in the reinforcement of Th1-dominated lung inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 521s
Year: 2001
Injury induced inflammasome activation leading to IL-1b and lung inflammation depends on IL-17
Source: Annual Congress 2010 - Stem cells and growth factors in lung injury
Year: 2010
Amifostine reduces lipopolysaccharide-induced lung dysfunction via suppression of redox-sensitive inflammatory signaling
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Decreased PTEN amplifies PI3K signaling and enhances pro-inflammatory cytokine release in COPD
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease
Source: Eur Respir J, 57 (6) 1900716; 10.1183/13993003.00716-2019
Year: 2021
N-acetyl cysteine inhibits IL-17-induced IL-8 production from human airway smooth muscle cells - a possible role for anti-oxidant treatment in chronic lung rejection?
Source: Eur Respir J 2003; 22: Suppl. 45, 202s
Year: 2003
Suppressed pulmonary expression of leptin in lipopolysaccharide-induced acute and chronic lung inflammation
Source: Eur Respir Rev 2006; 15: 207-208
Year: 2006
Soluble ADAM33 augments the pulmonary innate immune response promoting susceptibility to allergic airway inflammation
Source: International Congress 2018 – Translational models of the immunopathology that underlies airway obstructive diseases
Year: 2018
Adapalene abrogates erlotinib-induced skin disorder by regulating proinflammatory cytokine production from human epidermal cells
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019
Impaired lung function is associated with systemic inflammation and macrophage activation
Source: Eur Respir J 2015; 45: 557-559
Year: 2015
Latent TGF-ß binding protein 4 is an important factor that influences anti-inflammatory and cell-protective responses in the pathogenesis of pulmonary emphysema
Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease
Year: 2020
The protective effects of SIGIRR on flagellin-induced acute inflammation of the airway in mice
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Oral Presentation: Neutrophils augment LPS-mediated pro-inflammatory signaling in human lung epithelial cells
Source: Lung Science Conference 2011 - Immune system dysregulation in chronic lung disease
Year: 2011
Dysregulation of the “inflammatory reflex” with abnormal neurohumoral activation may contribute to proinflammatory activity driving the progression of COPD
Source: Eur Respir J, 51 (6) 1800806; 10.1183/13993003.00806-2018
Year: 2018
The PD-1 immune checkpoint promotes lung damage in murine models of COPD-like inflammation
Source: International Congress 2019 – Injury and repair: less is more
Year: 2019
Role of proinflammatory cytokines IL-18 and IL-1β in bleomycin-induced lung injury in humans and mice
Source: Annual Congress 2009 - Mechanisms of pulmonary inflammation and fibrosis
Year: 2009
Disturbance of pro-inflammatory cytokine production in patients with cystic fibrosis lung disease
Source: Eur Respir J 2005; 26: Suppl. 49, 404s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept